Publication:
Use of Intravitreal Bevacizumab Injection among Patients Undergoing Surgical Retinal Interventions at Tertiary Eye Hospital: A Descriptive Cross-sectional Study Authors

Simple item page
creativeworkseries.issnJNMA Print ISSN: 0028-2715; Online ISSN: 1815-672X
dc.contributor.authorShrestha, Arjun
dc.contributor.authorSuwal, Rinkal
dc.contributor.authorShrestha, Rajan
dc.contributor.authorSuwal, Barsha
dc.contributor.authorKhadka, Deepak
dc.date.accessioned2026-02-16T07:54:14Z
dc.date.available2026-02-16T07:54:14Z
dc.date.issued2021
dc.descriptionArjun Shrestha Department of Ophthalmology, BP Eye Foundation, Hospital for Children, Eye, ENT & Rehabilitation Services, Bagmati Province, Bhaktapur, Nepal https://orcid.org/0000-0002-5567-4841 Rinkal Suwal Department of Ophthalmology, BP Eye Foundation, Hospital for Children, Eye, ENT & Rehabilitation Services, Bagmati Province, Bhaktapur, Nepal https://orcid.org/0000-0002-2033-8610 Rajan Shrestha Academic and Research Department, BP Eye Foundation, Hospital for Children, Eye, ENT & Rehabilitation, Bagmati Province, Bhaktapur, Nepal https://orcid.org/0000-0002-0703-4655 Barsha Suwal Department of Ophthalmology, BP Eye Foundation, Hospital for Children, Eye, ENT & Rehabilitation Services, Bagmati Province, Bhaktapur, Nepal https://orcid.org/0000-0002-1548-3469 Deepak Khadka Department of Ophthalmology, BP Eye Foundation, Hospital for Children, Eye, ENT & Rehabilitation Services, Bagmati Province, Bhaktapur, Nepal https://orcid.org/0000-0001-8436-129X
dc.description.abstractAbstract: Introduction: Intravitreal Bevacizumab injection has now become a routine procedure for retina specialists throughout the world. Easy availability of this monoclonal antibody molecule even in Nepal has brought a revolution in the management of various retinal diseases. This study aims to find out the prevalence of the use of intravitreal Bevacizumab for retinal diseases at the tertiary eye hospital. Methods: This descriptive cross-sectional study was carried out in the retina department at a tertiary care hospital from January 2017 to December 2019 after obtaining ethical clearance from Nepal Health Research Council (Ref: 125/2020P). The sample size was calculated and the study enrolled all patients who received intravitreal Bevacizumab for retinal diseases using convenience sampling technique. Data were analyzed using Statistical Package for Social Science Version 21. Point estimate at 95% Confidence Interval was calculated, along with frequency and percentage for binary data. Results: Out of 959 total surgical retinal interventions done 296 (30.86%) at 95% Confidence Interval (27.93-33.78) patients received intravitreal Bevacizumab. Out of total intravitreal Bevacizumab injections, 143 (36.7%) injections were given to retinal vein occlusions patients, 127 (32.6%) injections were given to diabetic retinopathy patients and 66 (17%) injections was given to age-related macular degeneration patients. Males 176 (59.5%) outnumbered the females 120 (40.5%) in receiving intravitreal Bevacizumab. Mean baseline Logarithm of the Minimal Angle of Resolution visual acuity, 1.1, improved to, 0.75, after 3 months of intravitreal Bevacizumab. Conclusions: Intravitreal Bevacizumab was one of the commonest retinal interventions used. Retinal vein occlusion, diabetic retinopathy, and age-related macular degeneration were the commonest retinal diseases needing intravitreal Bevacizumab.
dc.identifierhttps://doi.org/10.31729/jnma.5515
dc.identifier.urihttps://hdl.handle.net/20.500.14572/4780
dc.language.isoen_US
dc.publisherNepal Medical Association
dc.subjectbevacizumab
dc.subjectintravitreal injection
dc.subjectvisual disorders
dc.titleUse of Intravitreal Bevacizumab Injection among Patients Undergoing Surgical Retinal Interventions at Tertiary Eye Hospital: A Descriptive Cross-sectional Study Authors
dc.typeArticle
dspace.entity.typePublication
local.article.typeOriginal Article
oaire.citation.endPage861
oaire.citation.startPage858
relation.isJournalIssueOfPublication0e66f2c1-5ba7-4efc-b90b-a0cf40ce18b8
relation.isJournalIssueOfPublication.latestForDiscovery0e66f2c1-5ba7-4efc-b90b-a0cf40ce18b8
relation.isJournalOfPublicatione6e146a0-0ece-4aba-aa0a-6ccfbd10a12a

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
858-861.pdf
Size:
232.7 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.86 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Publications

Connect with us

Nepal Health Research Council © 2026
Ramshah Path, Kathmandu Nepal P.O.Box 7626